Document is current
Any future updates will be listed below
-
Authors
Wu, Jingyi
Gonzalez Castro, L. Nicolas https://orcid.org/0000-0001-7699-5188
Battaglia, Sofia
El Farran, Chadi A. https://orcid.org/0000-0002-9374-103X
D’Antonio, Joshua P.
Miller, Tyler E.
Suvà, Mario L. https://orcid.org/0000-0001-9898-5351
Bernstein, Bradley E. https://orcid.org/0000-0002-5726-6278
- License Information
-
More Information
Article History
Received: 18 September 2023
Accepted: 18 October 2024
First Online: 21 November 2024
Competing interests
: L.N.G.C. has received research funding from Merck & Co. (to the Dana-Farber Cancer Institute) and has received consulting fees from Elsevier, Servier Laboratories, BMJ Best Practice, Prime Education and Oakstone Publishing. B.E.B. discloses financial interests in HiFiBio, Arsenal Biosciences, Chroma Medicine, Cell Signaling Technologies and Design Pharmaceuticals. M.L.S. discloses financial interests in Immunitas Therapeutics. T.E.M. discloses financial interest in Reify Health, Care Access Research and Telomere Diagnostics. The remaining authors declare no competing interests.
